Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2021-12-08
DOWNLOAD ISSUE
Donate

Sponsor


  WINDY CITY TIMES

PrEP options likely to change following Truvada patent expiration
by Matt Simonette
2021-03-04

This article shared 1962 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email


Among the myriad challenges facing HIV/AIDS advocates and healthcare providers has been increasing use of pre-exposure prophylaxis, or PrEP, among persons at risk for HIV transmission. A PrEP intervention, which usually consists of taking the oral medication Truvada, has been shown to decrease the risk of transmission by more than 90 percent.

Truvada was approved for PrEP use by the Food and Drug Administration in 2012 and, since then, has been widely prescribed by physicians to help at-risk patients prevent HIV transmission (it was earlier used to treat persons living with HIV). But Truvada's patent expiration in 2020 means both generic options for consumers are forthcoming and that a competing drug, Descovy, by the same manufacturer, is already on the market.

Some advocates are looking forward to having lower-cost options available. AIDS Foundation of Chicago (AFC) Senior Director of Prevention Advocacy and Gay Men's Health Jim Pickett suspects that "lower drug costs will lower the cost of access and alleviate some pressure on the system."

He added, "With PrEP, the costs are not just about the drug. There are costs affiliated with seeing your doctor, having blood work done, being tested for HIV and STI's. It's important to remember that services that come along with PrEP are part of the program—PrEP isn't just a prescription. If our system can spend less on the drug, there's arguably more money to cover those other things which can be prohibitive for people."

The cost of Truvada—which is a combination of the drugs known generically as tenofovir disoproxil fumarate and emtricitabine—has indeed been a key deterrent to widespread PrEP implementation. A month's supply of the medication is often $1,500-2,000. Nevertheless, many insurers cover Truvada in their formularies, and the medication's manufacturer, Foster City, California-based Gilead Sciences, provides consumer assistance for monthly co-payments their plans require.

Various public health agencies have also made PrEP access a central component to long-term strategies that eliminate new HIV transmissions, such as the Getting to Zero initiative launched in Illinois in late 2018. The federal government announced a similar program with PrEP interventions playing a central role in early 2019.

Nevertheless, PrEP adoption numbers remain far behind where advocates and providers want to see them. Getting the message about PrEP to white gay men has been a relatively minimal challenge, but communicating that same message to diverse audiences at risk, such as transgender women or young Black men, remains problematic. Usage in the southern United States, where a large number of new HIV transmissions take place, is also low.

In late 2019, Gilead announced it would donate a five-year supply of Truvada to 200,000 people. Their Truvada patent expired in late 2020. The company reached an exclusivity agreement for six months Israeli pharmaceutical manufacturer Teva for a generic version of tenofovir disoproxil fumarate and emtricitabine. Starting in spring 2021, Teva's exclusivity window expires and any manufacturer can produce a generic version of tenofovir disoproxil fumarate and emtricitabine.

Gilead still intends to remain a player in manufacturing and distributing medications for PrEP, however. In 2019, it received approval for use of Descovy as a PrEP intervention and has aggressively marketed the new drug as a replacement for Truvada. Google users who search "Truvada generic" will likely spot an advertisement for Descovy toward the top of their results.

Among the advantages of Descovy, according to Gilead, are reduced chances of complications to kidneys or bone density, which are stated side-effects to Truvada. But Descovy shares the same high cost as Truvada, about $16,600-20,000 a year, according to aidsmap.com .

Many advocates and providers say that there is no need for a "mass exodus" from Truvada to Descovy for PrEP users, Pickett said.

"In terms of prescribing for PrEP, the vast majority of people using Truvada for PrEP have absolutely zero clinical need to switch over to Descovy," he added. "The only clinical reason to switch would be if you have some underlying kidney or bone disease, or if Truvada is giving your kidneys a hard time."

Gilead could not provide a spokesperson to comment on Descovy by this article's deadline. Shortly after Descovy was approved for PrEP in October 2019, Daniel O'Day, Gilead's chairman and CEO, said the new medication nevertheless "provides a new HIV prevention option that matches Truvada's high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time."

Prior to her appointment as director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, was lead author on a March 2020 Annals of Internal Medicine study which concluded that mitigating for Truvada's side-effects with a new medication was outweighed by the benefits of a lower-cost generic substitute for Truvada. Other researchers also have expressed concern that Descovy has not been tested on as diverse a population as Truvada has been.

"We already are seeing insurance companies pointing people to the generic alternative—when you are prescribed PrEP, the insurance company might cover the generic form of Truvada," Pickett said. "They may or may not be inclined to cover Truvada itself. We are also seeing insurance companies put in utilization-management for Descovy, so if you are prescribed Descovy, the doctor has to show clinical need."

Gilead has also been involved in extensive litigation with the federal government regarding the PrEP-related patents. The CDC sued the company in 2019, maintaining that it had not been properly compensated for federal researchers' contributions to Truvada and Descovy's development. In January 2021, a federal judge rejected the Justice Department's motion to dismiss Gilead's counterclaims that the federal government had been in breach of key contracts, so the litigation will continue.

But for now, a key challenge for stakeholders remains getting the costs under control. Using PrEP represents a collective commitment of time and money for patients, providers and insurers.

In the years ahead, the PrEP landscape will likely change even further. An injectable version of the intervention has proven to be as effective as oral applications. In such a scenario, the medication cabotegravir could be injected and offer two months' worth of protection for patients who don't wish to take a pill every day.

Pickett said he didn't foresee injectable PrEP completely replacing pills however, noting that compliance challenges might only shift for some consumers. While the injection saves the patient from the responsibility of taking a pill, they'd still need a bimonthly appointment to receive it.

"I don't see it as replacing [oral medication]—I see it as being additive," Pickett said. "I see it drawing in people who struggle with PrEP because it is a pill, or aren't interested because it's a pill. Overall, if we do it right and create support systems that make it easy for people to get their shots—imagine being able to do it at Walgreens—I'll be super-excited about it. It means people having more options and more protection."


This article shared 1962 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email

  ARTICLES YOU MIGHT LIKE

Gay News

NATIONAL California report, AIDS foundation CEO, QueerArt, intersex bill 2022-01-09
- California law enforcement officials conduct body searches on Black and transgender people more often than on white and cisgender people, according to a new report from California's Racial and Identity Profiling Advisory (RIPA) Board, LGBTQ Na ...


Gay News

FDA approves injectable PrEP 2021-12-24
- The U.S. Food and Drug Administration (FDA) approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 77 pounds for pre-exposure prophylaxis (PrEP) to ...


Gay News

World of Chocolate fundraiser returns Feb. 11, benefits AIDS Foundation Chicago 2021-12-20
--From a press release - After a two-year hiatus, AIDS Foundation Chicago (AFC) is proud to announce the return of its famed World of Chocolate fundraiser taking place on Friday, Feb/ 11 at Union Station, 500 W. Jackson Blvd. Inspired by ...


Gay News

HIV AT 40: Longtime advocate Gregg Gonsalves talks activist roots, Larry Kramer and COVID 2021-12-08
- When it comes to dealing with HIV/AIDS, few people have been on the front lines—in the areas of activism, research and instruction—like Gregg Gonsalves. Gonsalves, a MacArthur fellow, is an expert in policy modeling on infectious ...


Gay News

AIDS Garden Chicago supporters, CDPH official commemorate World AIDS Day with event 2021-12-01
- AIDS Garden Chicago supporters and the Chicago Department of Public Health (CDPH) commemorated the 34th annual World AIDS Day on Dec. 1 at the Belmont Yacht Club with a sneak preview of the garden. The 2.5-acre ...


Gay News

Five Worth Finding: World AIDS Day, 'Benedetta,' books, wine in a can 2021-11-26
- —World AIDS Day event at Belmont Harbor: —The Chicago Parks Foundation will hold a World AIDS Day event on Dec. 1, 9-10:30 a.m., at the Belmont Harbor Yacht Club. Antonio King, LGBTQ health and outreach liaison ...


Gay News

World AIDS Day events on tap 2021-11-26
- World AIDS Day takes place every year on Dec. 1. During this year—which marks the 40th anniversary since HIV was officially discovered—here are some of the events taking place (locally, regionally and nationally) on, before and ...


Gay News

AFC commemorates passing of the HIV decriminalization law with World AIDS Day event Dec. 1 2021-11-24
--From a press release - The World AIDS Day Community Celebration of the Historic Passage of HB1063, which ended criminal penalties against people living with HIV, will be hosted by AIDS Foundation Chicago (AFC). It will also commemorate World AIDS Day ...


Gay News

AIDS Foundation Chicago awards grants to Black- and Latinx-led organizations 2021-11-12
- AIDS Foundation Chicago (AFC) has awarded eight grants—totaling $72,000—to BIPOC-led organizations working to address the HIV/AIDS crisis in Black and Latinx neighborhoods across Chicago. The grants came from AFC's Learning ...


Gay News

National AIDS Memorial to hold World AIDS Day national events Nov. 30 and Dec. 1 2021-11-10
--From a press release - SAN FRANCISCO (Nov. 9, 2021) — On December 1, the National AIDS Memorial brings three powerful programs to the public for World AIDS Day that offer inspiration, hope, remembrance, and reflection. The programming, free to the ...


Gay News

Secretary Becerra visits Humboldt Park, AIDS Foundation Chicago 2021-11-09
- On Nov. 8, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra traveled to sites in Chicago to highlight Biden-Harris administration's plans to build back better through investments in maternal health, the Affordable Ca ...


Gay News

LGBTQ+ Latinx healthcare providers discuss impact of COVID-19 pandemic 2021-10-29
- As part of its COVID-19 Grand Rounds series, AIDS Foundation Chicago hosted an Oct. 26 panel featuring LGBTQ+ Latinx healthcare providers sharing how the pandemic has impacted their personal and professional lives. Panelists included Howard Brown ...


Gay News

WORLD Indian commission, queer royals, MTV, Putin, attack in Jamaica 2021-10-24
- India's National Medical Commission has ordered publishers and medical schools to edit their textbooks and curricula to exclude discriminatory and unscientific portrayals of LGBTI people, according to Human Rights Watch. ...


Gay News

HHS awards $2.21B in FY2021 for HIV care, support services, medication 2021-10-05
--From a press release - The U.S. Department of Health and Human Services (HHS), announced approximately $2.21 billion in Ryan White HIV/AIDS Program funding for cities, counties, states, and local community-based organizations in fiscal year ...


Gay News

30th Annual AIDS Run & Walk raises more than $400K 2021-10-06
- CHICAGO — More than 1,800 advocates, community partners, runners, walkers, volunteers, staff members and more gathered at Soldier Field on Oct. 2 for the 30th annual AIDS Run & Walk Chicago. The event raised approximately $420,000 ...


 



Copyright © 2022 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 
 

TRENDINGBREAKINGPHOTOS







Sponsor
Sponsor


 



Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.